Hirofumi Tsuzuki
Hirofumi Tsuzuki has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Tatsuya Kawase
Astellas Pharma Inc
12 shared publications - Atsushi Suzuki
Mayo Clinic (United States)
11 shared publications - Aya Kikuchi
Astellas Pharma Inc., Tsukuba, Japan
11 shared publications - Hideyuki Watanabe
Astellas Pharma Inc., Tsukuba, Japan
11 shared publications - Jane Weng
Astellas Pharma Inc., Tsukuba, Japan
11 shared publications - Kazuya Yamano
Astellas Pharma Inc., Tsukuba, Japan
11 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 enhanced up-regulation of activation markers in T cells in vivo. A and B, Expression profiles of CD25 and CD69 are shown. C and D, Scatter plots indicate the individual proportion of CD25+ or CD69+ cells in T cells. E and F, Scatter plots indicate the individual geometric mean fluorescence intensity (gMFI) of CD25 or CD69. The mean ± SEM were expressed as short horizontal lines and error bars (n = 3). ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, *: P < 0.05, ns: not significant, compared with the vehicle group (unpaired Student’s t test).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 enhanced up-regulation of activation markers in T cells in vivo. A and B, Expression profiles of CD25 and CD69 are shown. C and D, Scatter plots indicate the individual proportion of CD25+ or CD69+ cells in T cells. E and F, Scatter plots indicate the individual geometric mean fluorescence intensity (gMFI) of CD25 or CD69. The mean ± SEM were expressed as short horizontal lines and error bars (n = 3). ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, *: P < 0.05, ns: not significant, compared with the vehicle group (unpaired Student’s t test).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Plasma concentrations and pharmacokinetic parameters of ASP1570 after repeated oral administration to a B16F1 syngeneic mouse model. Pharmacokinetic parameters were calculated from the mean concentration of 3 mice at each time point. Administration time (once-daily) = 0 h. AUCt: area under the concentration-time curve from time 0 to time at which the last measurable concentration was observed, Cmax: maximum concentration, tmax: time to reach maximum concentration.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Plasma concentrations and pharmacokinetic parameters of ASP1570 after repeated oral administration to a B16F1 syngeneic mouse model. Pharmacokinetic parameters were calculated from the mean concentration of 3 mice at each time point. Administration time (once-daily) = 0 h. AUCt: area under the concentration-time curve from time 0 to time at which the last measurable concentration was observed, Cmax: maximum concentration, tmax: time to reach maximum concentration.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
List of compounds, assays, reagents, cells, and antibodies used in the methods. Cell lines were passaged for < 6 months after receiving or reviving cells from vendors that perform internal authentication, so authentication was not repeated in-house. Mycoplasma testing was conducted regularly by a core facility.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
List of compounds, assays, reagents, cells, and antibodies used in the methods. Cell lines were passaged for < 6 months after receiving or reviving cells from vendors that perform internal authentication, so authentication was not repeated in-house. Mycoplasma testing was conducted regularly by a core facility.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Gating strategy employed for flow cytometry. A, The intratumoral cells were gated by FSC and SSC, followed by live single cells, CD45+, NK, and CD3+ T cell gating. B, Gated CD3+ T cells were gated on CD8a+ or CD4+ T cells. C, Gated CD4+ T cells were gated on CD25+Foxp3+ Treg cells. D-G, TIL analysis of intratumoral NK cells as in Fig. 5 (n = 10). D, E, and G, Scatter plots indicate the individual % or absolute number of cells and mean ± SEM are expressed as short horizontal lines and error bars. F, Expression profiles of representative data are shown. ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, ns: not significant, compared with the vehicle group (unpaired Student’s t test).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Gating strategy employed for flow cytometry. A, The intratumoral cells were gated by FSC and SSC, followed by live single cells, CD45+, NK, and CD3+ T cell gating. B, Gated CD3+ T cells were gated on CD8a+ or CD4+ T cells. C, Gated CD4+ T cells were gated on CD25+Foxp3+ Treg cells. D-G, TIL analysis of intratumoral NK cells as in Fig. 5 (n = 10). D, E, and G, Scatter plots indicate the individual % or absolute number of cells and mean ± SEM are expressed as short horizontal lines and error bars. F, Expression profiles of representative data are shown. ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, ns: not significant, compared with the vehicle group (unpaired Student’s t test).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Studies of diacylglycerol kinase ζ (DGKζ) in DGKζ knockout mice have revealed its role as an intracellular immune checkpoint in T cells. Although enhancing antitumor immunity by pharmacologic inhibition of DGKζ is desirable, selective DGKζ inhibitors for clinical use remain largely unexplored. In this study, we report a novel, small-molecule DGKζ inhibitor, ASP1570, which is currently under phase 1 development (NCT05083481), and characterize its effect on potential resistance mechanisms against approved immune checkpoint inhibitors in multiple immunosuppressive conditions: not only TGF-β, prostaglandin E2, adenosine, and PD-1 but also cytotoxic T-lymphocyte antigen-4 and T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif. First, our findings indicated that ASP1570 exhibited an inhibitory effect on the kinase activity of DGKζ. Unexpectedly, we observed that DGKζ protein was degraded in cells treated with ASP1570 in a proteasome-dependent manner. ASP1570 enhanced T-cell activation with increased diacylglycerol downstream signaling and released anergic T cells from their hyporesponsive state. Furthermore, ASP1570 restored T-cell functions suppressed by multiple immunosuppressive signals (TGF-β, prostaglandin E2, adenosine, PD-1, cytotoxic T-lymphocyte antigen-4, and T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif) and induced tumor growth inhibition in two types of syngeneic mouse models: anti–PD-1 antibody–sensitive MC38 and anti–PD-1 antibody–insensitive B16F1/F10. The antitumor efficacy of ASP1570 was canceled by CD8+ T-cell depletion, indicating that its antitumor effect depends on CD8+ cytotoxic T-cell activation. Collectively, ASP1570 potentially improves antitumor efficacy in both anti–PD-1 therapy–resistant and anti–PD-1 therapy–responsive tumors by overcoming multiple immunosuppressive signals.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Studies of diacylglycerol kinase ζ (DGKζ) in DGKζ knockout mice have revealed its role as an intracellular immune checkpoint in T cells. Although enhancing antitumor immunity by pharmacologic inhibition of DGKζ is desirable, selective DGKζ inhibitors for clinical use remain largely unexplored. In this study, we report a novel, small-molecule DGKζ inhibitor, ASP1570, which is currently under phase 1 development (NCT05083481), and characterize its effect on potential resistance mechanisms against approved immune checkpoint inhibitors in multiple immunosuppressive conditions: not only TGF-β, prostaglandin E2, adenosine, and PD-1 but also cytotoxic T-lymphocyte antigen-4 and T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif. First, our findings indicated that ASP1570 exhibited an inhibitory effect on the kinase activity of DGKζ. Unexpectedly, we observed that DGKζ protein was degraded in cells treated with ASP1570 in a proteasome-dependent manner. ASP1570 enhanced T-cell activation with increased diacylglycerol downstream signaling and released anergic T cells from their hyporesponsive state. Furthermore, ASP1570 restored T-cell functions suppressed by multiple immunosuppressive signals (TGF-β, prostaglandin E2, adenosine, PD-1, cytotoxic T-lymphocyte antigen-4, and T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif) and induced tumor growth inhibition in two types of syngeneic mouse models: anti–PD-1 antibody–sensitive MC38 and anti–PD-1 antibody–insensitive B16F1/F10. The antitumor efficacy of ASP1570 was canceled by CD8+ T-cell depletion, indicating that its antitumor effect depends on CD8+ cytotoxic T-cell activation. Collectively, ASP1570 potentially improves antitumor efficacy in both anti–PD-1 therapy–resistant and anti–PD-1 therapy–responsive tumors by overcoming multiple immunosuppressive signals.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Inhibitory effect of ASP1570 on human DGK enzymes (A) and mouse DGKζ (B). Each DGK enzyme activity is shown as mean ± SEM of 3 independent assays performed in triplicate.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Inhibitory effect of ASP1570 on human DGK enzymes (A) and mouse DGKζ (B). Each DGK enzyme activity is shown as mean ± SEM of 3 independent assays performed in triplicate.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 restored the Tresp response to Treg suppression. Tresp and Treg cells were co-cultured at various ratios for 6 days, and proliferation of Tresp cells was measured. A, The representative data of Tresp proliferation at various ratios of Tresp/Treg are shown. B, The representative data from at least three independent assays are shown as the mean ± SD. ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, ns: not significant, compared with the DMSO group (unpaired Student’s t test).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 restored the Tresp response to Treg suppression. Tresp and Treg cells were co-cultured at various ratios for 6 days, and proliferation of Tresp cells was measured. A, The representative data of Tresp proliferation at various ratios of Tresp/Treg are shown. B, The representative data from at least three independent assays are shown as the mean ± SD. ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, ns: not significant, compared with the DMSO group (unpaired Student’s t test).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Inhibitory effect of ASP1570 on various human kinases. The geometric mean and 95% confidential interval of IC50 values were calculated from 3 independent assays performed in duplicate.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
Inhibitory effect of ASP1570 on various human kinases. The geometric mean and 95% confidential interval of IC50 values were calculated from 3 independent assays performed in duplicate.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
List of fluorophore-conjugated antibodies and dyes to distinguish dead cells used for staining for flow cytometry.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
List of fluorophore-conjugated antibodies and dyes to distinguish dead cells used for staining for flow cytometry.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 reinvigorated anergic Jurkat T cells. IL-2 production in A, normal Jurkat cells; B, anti-CD3-induced anergic Jurkat cells; and C, ionomycin-induced anergic Jurkat cells. The data are shown as the mean ± SEM of 3 independent assays. **: P < 0.01, *: P < 0.05, compared with the anti-CD3/CD28 (+) test substance (-) group (A), anti-CD3/CD28 (+) ASP1570 (-) in anergic cells group (B and C) (Dunnett’s multiple comparison test).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
ASP1570 reinvigorated anergic Jurkat T cells. IL-2 production in A, normal Jurkat cells; B, anti-CD3-induced anergic Jurkat cells; and C, ionomycin-induced anergic Jurkat cells. The data are shown as the mean ± SEM of 3 independent assays. **: P < 0.01, *: P < 0.05, compared with the anti-CD3/CD28 (+) test substance (-) group (A), anti-CD3/CD28 (+) ASP1570 (-) in anergic cells group (B and C) (Dunnett’s multiple comparison test).